Niagen Bioscience (NAGE) EBITDA Margin (2010 - 2026)
Niagen Bioscience (NAGE) reported EBITDA Margin of 5.01% for Q1 2026, down 1065.0% year-over-year from 0.52% in Q1 2025, and down 58.53% quarter-over-quarter from 12.07% in Q4 2025.
Niagen Bioscience (NAGE) EBITDA Margin (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 17 years of EBITDA Margin data on file, last reported at 5.01% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 5.01%, down 1065.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.03% (down 223.0% YoY), and the FY2025 annual result was 12.58%, up 482.0% from the prior year.
- EBITDA Margin fell to 5.01% in Q1 2026 per NAGE's latest filing, from 12.07% in the prior quarter.
- Over five years, EBITDA Margin peaked at 24.42% in Q4 2024 and troughed at 44.8% in Q1 2022.
- A 5-year average of 3.11% and a median of 1.13% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2025: EBITDA Margin soared 3607 bps in 2023, then slumped 1234 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 6.88% in 2022, then soared by 88 bps to 0.79% in 2023, then jumped by 3180 bps to 24.42% in 2024, then sank by 51 bps to 12.07% in 2025, then plunged by 59 bps to 5.01% in 2026.
- Business Quant data shows NAGE's EBITDA Margin at 5.01% in Q1 2026, 12.07% in Q4 2025, and 12.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Niagen Bioscience | 280.11 Mn | 213.56 Mn | 19.98 Mn | 5.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.01% |
| Dec 31, 2025 | 12.07% |
| Sep 30, 2025 | 12.46% |
| Jun 30, 2025 | 10.24% |
| Mar 31, 2025 | 15.66% |
| Dec 31, 2024 | 24.42% |
| Sep 30, 2024 | 6.26% |
| Jun 30, 2024 | -1.13% |
| Mar 31, 2024 | -3.30% |
| Dec 31, 2023 | -0.79% |
| Sep 30, 2023 | -5.88% |
| Jun 30, 2023 | -11.40% |
| Mar 31, 2023 | -8.72% |
| Dec 31, 2022 | -6.88% |
| Sep 30, 2022 | -17.96% |
| Jun 30, 2022 | -38.17% |
| Mar 31, 2022 | -44.80% |
| Dec 31, 2021 | -29.93% |
| Sep 30, 2021 | -51.08% |
| Jun 30, 2021 | -31.38% |